科伦药业：关于子公司核心产品博度曲妥珠单抗治疗2L+HER2+乳腺癌获国家药品监督管理局批准上市的公告

Core Viewpoint - The announcement from Kelun Pharmaceutical indicates that its subsidiary, Sichuan Kelun Botai Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate (ADC) A166 (also known as Shutailai®) for the treatment of adult patients with HER2-positive breast cancer who have previously received one or more anti-HER2 therapies [2] Group 1 - The approved drug A166 targets the human epidermal growth factor receptor 2 (HER2) [2] - The indication for A166 is for patients with unresectable or metastatic HER2-positive breast cancer [2] - The approval is significant as it addresses a patient population that has limited treatment options after prior therapies [2]